Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Drug Induced Liver Disease
How do you counsel patients on the use and risks of alternative medications and supplements given how prevalent and easily accessible they are to the average person and their risk of liver injury?
Related Questions
How would you approach the management of drug-induced autoimmune hepatitis compared to non-drug-induced autoimmune hepatitis?
When do you pursue liver biopsy for assessment of DILI?
Is there a serum ammonium level for which you recommend initiation of dialysis in a patient with hepatic encephalopathy?
For how long would you treat a patient with latent TB before allowing them to proceed with a liver transplant?
What role is there for the assessment of hepatitis B virus genotype as it pertains to pharmacologic therapy and HCC screening?
How do you approach risk of development of PTLD in liver transplant recipients with positive EBV antibodies and/or viral loads?
How do you balance infection risk in patients with immune-mediated liver disease on chronic immunosuppression (ex: prednisone, AZA, MMF, etc)?
What is your clinical approach to the evaluation of cytopenias in patients with end-stage liver disease?
In what scenario do you obtain ammonia levels in a patient with cirrhosis?
How do you approach a patient who has incidentally found liver and renal cysts?
